IL-7

OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”

Retrieved on: 
Tuesday, October 12, 2021
IL-7, Large-cell lung carcinoma, Mab, Degenerative disease, Veloxis Pharmaceuticals, Inflammation, B cell, OSE, COVID-19, R, Gustave Roussy, Tissue, Failure, Macrophage, ICI, Nivolumab, Boehringer Ingelheim, Cancer, Fortification, Vaccination, Clinical research, Immunotherapy, Immune system, Severe acute respiratory syndrome coronavirus 2, Ulcerative colitis, Partnership, Patient, PD-1, Research, Pancreatic cancer, Autoimmune disease, Epitope, Fine chemical, Pharmaceutical industry, Vaccine

Recent clinical data supporting development of first-in-class CD47/SIRP pathway targeting antibody BI 765063 alone and in combination with anti-PD-1 ezabenlimab in solid tumours.

Key Points: 
  • Recent clinical data supporting development of first-in-class CD47/SIRP pathway targeting antibody BI 765063 alone and in combination with anti-PD-1 ezabenlimab in solid tumours.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®

Retrieved on: 
Monday, October 11, 2021
ISIN, IL-7, Patent, Large-cell lung carcinoma, Mab, Non-small-cell lung carcinoma, Degenerative disease, Veloxis Pharmaceuticals, Inflammation, B cell, European Patent Office, OSE, COVID-19, ESMO, Mnemos EP, Tissue, NSCLC, Failure, Macrophage, GLOBE, Nivolumab, Boehringer Ingelheim, European Society for Medical Oncology, Cancer, Fortification, Vaccination, Immunotherapy, Immune system, European Patent Convention, Severe acute respiratory syndrome coronavirus 2, Ulcerative colitis, Oncology, Congress, Patient, ICIS, Partnership, PD-1, Research, Pancreatic cancer, Autoimmune disease, Epitope, Pharmaceutical industry, Fine chemical, Vaccine

This new patent notice of allowance granted in Europe reinforces the patent protection for Tedopi and confirms an optimized industrial manufacturing process using a ready-to-use peptide emulsion.

Key Points: 
  • This new patent notice of allowance granted in Europe reinforces the patent protection for Tedopi and confirms an optimized industrial manufacturing process using a ready-to-use peptide emulsion.
  • Tedopi has shown positive final results from the Atalante 1 Phase 3 study in non-small cell lung patients after secondary resistance to immune checkpoint inhibitors (presented at the 2021 ESMO (European Society for Medical Oncology) Congress ).
  • Such combinations will further reinforce the therapeutic value of Tedopi in late-stage cancer indications.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, October 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Infection, Eli Lilly, Novartis, GSK, Society for Immunotherapy of Cancer, Immunity, Cancer, Patient, Pancreatic cancer, PricewaterhouseCoopers, IL-7, Clinical data management system, NIT, KOSDAQ, Company, Immunotherapy, Long-acting reversible contraception, Amgen, BMS, SITC, Industry, Society, Pharmaceutical industry, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

IL-7 is a fundamental cytokine for nave and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases).

Key Points: 
  • IL-7 is a fundamental cytokine for nave and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases).
  • In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments.
  • NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colore

Retrieved on: 
Thursday, September 30, 2021
ISIN, CD47, Standard of care, Pancreatic cancer, Clinical trial, Endometrium, Safety, ESMO, Veloxis Pharmaceuticals, Step, Macrophage, OSE, Degenerative disease, MSS, Inflammation, IL-7, Immune system, Mab, Disease, Ulcerative colitis, Boehringer Ingelheim, Vaccination, Neoplasm, Index (publishing), Partnership, Patient, Mnemos EP, Epitope, Toxicity, PD-1, Large-cell lung carcinoma, Fortification, Cancer, Myelocyte, Severe acute respiratory syndrome coronavirus 2, Tissue, B cell, Autoimmune disease, BI, GLOBE, MTD, Immunotherapy, ASCO, COVID-19, Nivolumab, Research, Colorectal cancer, Pharmaceutical industry, Vaccine, Fine chemical

Dosing of first patient in the expansion phase triggers a milestone payment of 8 million from Boehringer Ingelheim to OSE Immunotherapeutics.

Key Points: 
  • Dosing of first patient in the expansion phase triggers a milestone payment of 8 million from Boehringer Ingelheim to OSE Immunotherapeutics.
  • BI 765063 is a first-in-class SIRP inhibitor on the CD47/ SIRP Dont eat me pathway being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.
  • The dose escalation part of the Phase 1 trial (Step 1), evaluating BI 765063 alone and in combination with ezabenlimab, has been completed with a total of 18 patients enrolled in combination.
  • BI 765063 is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRP.

Beer Institute Honors Bill Hackett with Jeff Becker Beer Industry Service Award

Retrieved on: 
Monday, September 27, 2021
Constellation, Beer, Instagram, Sound, Association, IL-7, Beer Institute, Public policy, Twitter, CEO, Pabst, Leadership, Creativity, Retirement, Government, Constellation Brands, Industry, GLOBE

WASHINGTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Today, the Beer Institute awarded Bill Hackett, former executive vice president and chairman at Constellation Brands Beer Division, with the 2021 Jeff Becker Beer Industry Service Award for his leadership and dedication to the beer industry and Americas beer drinkers.

Key Points: 
  • WASHINGTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Today, the Beer Institute awarded Bill Hackett, former executive vice president and chairman at Constellation Brands Beer Division, with the 2021 Jeff Becker Beer Industry Service Award for his leadership and dedication to the beer industry and Americas beer drinkers.
  • The Beer Institute presented Bill with the award as part of its Annual Membership Meeting in Washington, D.C.
    Bill is one of the cornerstones of the American beer industry.
  • Congratulations Bill on being recognized for this years Jeff Becker Beer Industry Service Award.
  • For additional updates from the Beer Institute, visit our website ,follow @BeerInstitute on Twitter, like the Beer Institute on Facebook ,and follow the Beer Institute on Instagram .

OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021

Retrieved on: 
Monday, September 27, 2021
Macrophage, Partnership, OSE, Pancreatic cancer, Degenerative disease, Cancer, Inflammation, Patient, IL-7, Epitope, Immune system, Immunotherapy, Mab, PD-1, Large-cell lung carcinoma, Fortification, COVID-19, Nivolumab, Ulcerative colitis, Severe acute respiratory syndrome coronavirus 2, Research, Tissue, B cell, Autoimmune disease, Veloxis Pharmaceuticals, Boehringer Ingelheim, Vaccination, Vaccine, Pharmaceutical industry

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Key Points: 
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.
  • In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the European Society for Medical Oncology (ESMO) Virtual Congress 2021

Retrieved on: 
Monday, September 20, 2021
Macrophage, Partnership, OSE, Pancreatic cancer, Degenerative disease, Cancer, Inflammation, Patient, IL-7, Epitope, Immune system, Immunotherapy, Mab, PD-1, Large-cell lung carcinoma, Fortification, COVID-19, Nivolumab, Ulcerative colitis, Severe acute respiratory syndrome coronavirus 2, Research, Tissue, B cell, Autoimmune disease, Veloxis Pharmaceuticals, Boehringer Ingelheim, Vaccination, Vaccine, Pharmaceutical industry

The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.

Key Points: 
  • The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.
  • Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:
    Tedopi (innovative combination of neoepitopes): the companys most advanced product; positive final results of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients post-ICI failure.
  • In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

Retrieved on: 
Thursday, September 16, 2021
CEO, Vaccination, Index (publishing), Immune system, Cancer, Patient, Veloxis Pharmaceuticals, Neoplasm, Inflammation, OSE, Large-cell lung carcinoma, Mnemos EP, Colorectal cancer, Research, Oncology, BI, Fortification, Clinical trial, Conference, MSS, Step, Endometrial cancer, Nivolumab, COVID-19, Myelocyte, B cell, GLOBE, European Society for Medical Oncology, Infrared spectroscopy correlation table, Immunotherapy, ISIN, MSI, Tissue, ESMO, Epitope, Pancreatic cancer, MTD, Ulcerative colitis, Macrophage, Endometrium, ASCO, Autoimmune disease, Event-driven architecture, Severe acute respiratory syndrome coronavirus 2, Boehringer Ingelheim, Degenerative disease, CD47, Partnership, PD-1, IL-7, HCC, Pharmaceutical industry, Medical imaging, Palladium, Vaccine

BI 765063, a first-in-class SIRP inhibitor in the SIRP/CD47 Dont eat me pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.

Key Points: 
  • BI 765063, a first-in-class SIRP inhibitor in the SIRP/CD47 Dont eat me pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.
  • The dose escalation part (Step 1) of the Phase 1 trial evaluating BI 765063 alone and in combination with BI 754091 (ezabenlimab) in advanced solid tumors has been completed.
  • The study is being conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to BI 765063.
  • BI 765063 (OSE-172, anti-SIRP mAb in CD47/SIRP pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 results in monotherapy and BI 765063 dose escalation study ongoing in combination with Ezabenlimab (PD-1 antagonist).

NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, September 13, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Amgen, GSK, Pakistan Society of Neuro-Oncology, Novartis, Immunity, Patient, NIT, Society, Eli Lilly, Company, Chemoradiotherapy, Safety, BMS, Infection, Industry, KOSDAQ, PricewaterhouseCoopers, SNO, George Washington University School of Engineering and Applied Science, IL-7, Cancer, Pharmaceutical industry, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

The study evaluates the safety and efficacy of NT-I7, a novel long-acting human IL-7, given concurrently with adjuvant chemotherapy in patients with high-grade gliomas.

Key Points: 
  • The study evaluates the safety and efficacy of NT-I7, a novel long-acting human IL-7, given concurrently with adjuvant chemotherapy in patients with high-grade gliomas.
  • In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
  • The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the Company) that are based on its beliefs and expectations about the future.

Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

Retrieved on: 
Monday, September 13, 2021

This Phase 1 clinical trial aims to evaluate the safety and efficacy of BI 765063 as monotherapy and in combination with ezabenlimab (BI 754091; anti-PD-1 mAb) in patients with advanced solid tumors.

Key Points: 
  • This Phase 1 clinical trial aims to evaluate the safety and efficacy of BI 765063 as monotherapy and in combination with ezabenlimab (BI 754091; anti-PD-1 mAb) in patients with advanced solid tumors.
  • As of April 2021, a total of 12 patients had received at least one or more doses of each therapy.
  • The Phase 1 clinical study of BI 765063 is being conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to the product.
  • BI 765063 (OSE-172, anti-SIRP mAb on SIRP/CD47 pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 results in monotherapy and BI 765063 dose escalation study ongoing in combination with Ezabenlimab (PD-1 antagonist).